Technology | Artificial Intelligence | November 20, 2018

Philips Launches IntelliSpace Discovery Research Platform at RSNA

Open platform offers radiologists comprehensive data analytics to support development and deployment of artificial intelligence assets in radiology

Philips Launches IntelliSpace Discovery Research Platform at RSNA

November 20, 2018 — Ahead of the 2018 Radiological Society of North America Annual Meeting (RSNA), Nov. 25-30 in Chicago, Philips announced the introduction of the IntelliSpace Discovery 3.0 platform. IntelliSpace Discovery 3.0 is a comprehensive, open platform to enable the development and deployment of artificial intelligence (AI) assets in radiology, with the aim to support radiologists in their clinical and translational research.

Solutions that leverage AI have the potential to improve patient care and increase the efficiency of care delivery. However, there are challenges when it comes to introducing AI into healthcare clinical practice. Health systems are consistently faced with questions on how to collect and prepare high-quality data, which methods of training and validating the tools are most appropriate, and how to deploy AI without disruption. Philips combines AI and other technologies with knowledge of the clinical and operational context in which they are used – a people-centered approach called ‘adaptive intelligence’ – to develop integrated solutions that adapt to the needs of healthcare providers.

IntelliSpace Discovery is already used for the development of radiology applications for rendering, segmentation and quantification. For example, it is being used for research and clinical validation, and subsequently the tools/applications can be deployed into the radiology workflow on the Philips IntelliSpace Portal. With the introduction of IntelliSpace Discovery 3.0, the platform now provides research applications and tools for radiologists to aggregate, normalize and anonymize data, which can be visualized and annotated to ‘train’ and validate deep learning algorithms. They can then easily deploy these algorithms as plug-in apps into the research workflow to analyze new datasets and help facilitate clinical research in radiology, oncology, neurology and cardiology.

“We use IntelliSpace Discovery to bring our research activities to the next level. Everybody is talking about artificial intelligence. We are making our own deep learning AI algorithms,” said Prof. David Maintz, head of the Department of Radiology of the University Hospital Cologne in Germany.

The building blocks of IntelliSpace Discovery include:

  • Front End Applications – Integration with existing clinical infrastructure provides seamless access to vendor-agnostic and multimodality data-sets, and research advanced visualization tools allow data to be prepared and processed for AI training with existing AI tools;
  • Study Management – Fully scalable infrastructure contains a vendor-neutral research archive for structured and unstructured data, used to upload and process data;
  • Machine Learning – Research data and deployment platform obtains batch processing in a scalable, high-performance computing environment to support iterative development and validation;  
  • Clinical Research – AI assets and capabilities include multi-parametric enablement, segmentation and annotation, tumor quantification and stratification, deep learning networks and classification; and
  • Research Services – Accessibility to Philips research and development (R&D) for a range of services from consultancy to development.

Philips IntelliSpace Discovery is for research use only and cannot be used for patient diagnosis or treatment selection.

Another example of a solution showcased at RSNA that is powered by adaptive intelligence is Philips Illumeo. Pulling data from various hospital sources, this intelligent software presents a holistic view of the patient and provides relevant tools that adapt to physician needs, offering insights and standardizing their workflow based on their own preferences.

Jeroen Tas, chief innovation and strategy officer, Philips, will host a fireside session on how radiologists can integrate the power of artificial intelligence in their research workflows, taking place on Monday, Nov. 26, at 1:45 p.m. Central in the PhilipsLive! Forum in the Philips booth. He will be joined by Michael Knopp, M.D., Ph.D., director of the Wright Center of Innovation in Biomedical Imaging and a member of the Translational Therapeutics Program at the Ohio State Univeresity Comprehensive Cancer Center (OSUCCC) and Michael Perkuhn, M.D., MSc., Philips research informatics expert in the field in the field of molecular medicine and medical imaging.

Philips’ Homer Pien will also be presenting on “Adaptive Intelligence and radiology efficiency,” on Monday, Nov. 26, at 11:30 a.m. Central in the Machine Learning Showcase. Philips is also participating in a corporate symposium on “Artificial Intelligence: The impact and implications to radiology,” on Tuesday, Nov. 27 from 9:00 – 10:30 a.m. Central. The expert-led discussion will focus on the benefits of incorporating AI within the radiology space, including identification and worklist prioritization, workflow efficiency and productivity, and supporting clinical diagnosis and treatment.

For more information: www.usa.philips.com/healthcare

Related Content

Cloud services have been utilized within healthcare organizations for more than a decade. Now with the growth of artificial intelligence (AI) it is very common to see organizations adopting cloud services.

Getty Images

Feature | Information Technology | September 14, 2021 | By Jef Williams
To get more flexibility and cost savings from storage, healthcare organizations are increasing their investments in the cloud
News | Information Technology | September 14, 2021 | By Kumar Goswami
Figure 1: MWT Schematic of a typical setup for detecting malignant tissues/tumors.

Figure 1: MWT Schematic of a typical setup for detecting malignant tissues/tumors.

Feature | Radiology Imaging | September 14, 2021 | By Brendon McHugh
As with all imaging technologies, COVID-19 is expected to continue to negatively impact the market.

Courtesy of Grand View Research

Feature | Magnetic Resonance Imaging (MRI) | September 14, 2021 | By Melinda Taschetta-Millane
Us2.ai, a Singapore-based medtech firm backed by Sequoia India and EDBI, has received U.S. Food and Drug Administration (FDA) clearance for Us2.v1, a completely automated AI decision support tool for cardiac ultrasound.
News | Cardiovascular Ultrasound | September 14, 2021
September 14, 2021 – Us2.ai, a Singapore-based medtech firm backed by Sequoia India and EDBI, has received U.S.
Plan to attend RSNA21 at McCormick Place Chicago, Nov. 28 – Dec. 2, 2021

Getty Images

News | RSNA | September 13, 2021
September 13, 2021 — The Radiological Society of North America (RSNA) today announced highlights of the Technical Exh
New recommendations will help provide more reliable, reproducible results for MRI-based measurements of cartilage degeneration in the knee, helping to slow down disease and prevent progression to irreversible osteoarthritis, according to a special report published in the journal Radiology

Knee cartilage compartments with anatomic labels implemented in lateral (left side), central (middle), and medial (right side) MRI obtained with an intermediate weighted fat-saturated fast-spin-echo sequence (top row) and a spin-lattice relaxation time constant in rotating frame (T1r) magnetization-prepared angle-modulated partitioned k-space spoiled gradient echo snapshots sequence (bottom row, T1r maps). Study was performed without administration of intravenous gadolinium-based contrast material. The lateral femur (LF)/medial femur (MF) and lateral tibia (LT)/medial tibia (MT) can be further divided into subcompartments on the basis of meniscus anatomy according to Eckstein et al. P = patella, T = trochlea.  Chalian et al, Radiology 2021 301; 7 ©RSNA 2021

News | Magnetic Resonance Imaging (MRI) | September 10, 2021
September 10, 2021 — New recommendations will help provide more reliable, reproducible results for...
This certification, which covers Agfa HealthCare’s Class IIa Enterprise Imaging and XERO Viewer solutions, ensures that Agfa HealthCare can continue to deliver to customers innovative solutions that meet their real challenges and address their needs and requirements.
News | Enterprise Imaging | September 09, 2021
September 9, 2021 — Agfa HealthCare is proud to be one of the first companies to receive the new European Medical Dev
Laws designed to help women with increased risk for missed breast cancer diagnoses may help catch the disease earlier, according to Penn State College of Medicine researchers.

Getty Images | AleksandarNakic

News | Breast Imaging | September 09, 2021
September 9, 2021 — Laws designed to help women with increased risk for...